

Model:

Diameter of balloon (mm)	Effective length of balloon (mm)					
	10	15	17	20	26	30
2.00	G2.00-10	G2.00-15	G2.00-17	G2.00-20	G2.00-26	G2.00-30
2.50	G2.50-10	G2.50-15	G2.50-17	G2.50-20	G2.50-26	G2.50-30
2.75	G2.75-10	G2.75-15	G2.75-17	G2.75-20	G2.75-26	G2.75-30
3.00	G3.00-10	G3.00-15	G3.00-17	G3.00-20	G3.00-26	G3.00-30
3.50	G3.50-10	G3.50-15	G3.50-17	G3.50-20	G3.50-26	G3.50-30
4.00	G4.00-10	G4.00-15	G4.00-17	G4.00-20	G4.00-26	G4.00-30

Compliance table:

Pressure (atm)	Balloon length (mm)					
	2.00	2.50	2.75	3.00	3.50	4.00
2	1.87	2.36	2.59	2.82	3.29	3.77
4	1.94	2.43	2.67	2.91	3.39	3.89
6	2.00	2.50	2.75	3.00	3.50	4.00
8Nominal pressure	2.06	2.57	2.83	3.09	3.61	4.11
10	2.13	2.64	2.91	3.18	3.71	4.23
12	2.19	2.71	2.98	3.27	3.82	4.34
14Rated bursting pressure	2.25	2.78	3.06	3.36	3.92	4.45
16	2.32	2.85	3.14	3.45	4.03	4.57
18	2.38	2.92	3.22	3.54	4.14	4.68

Flowty™

Drug-eluting PTCA balloon dilatation catheter




Pure matrix,
crystal delivery

Novel needle shaped PTX microparticles

Novel needle-shaped PTX microparticles

Clinical result

Drug coating under electron microscope




Paclitaxel


- **Needle-shaped PTX microparticles**—drug coating is more efficient.
Without excipients, ensuring the purity of paclitaxel.
Drug coating is more uniform, more stable.
Conducive to high transfer rate of blood vessel.
- **Needle-shaped PTX microparticles**—long term maintenance of effective drug concentration

Semi-compliant balloon

- Very small passing diameter
- Excellent passability
- Excellent push performance




● **Primary endpoint: Lumen loss in target lesions during later period at ninth month.**




211 patients with coronary stent restenosis, coronary angiography and clinical follow-up observations were performed at ninth month after the operation:

	Flowty™	SeQuent® Please	P value
Preoperative target lesion stenosis degree (%)	67.65±16.56	66.76±13.78	0.657
Restenosis within the target lesion segment after 9 months (%)	10.34	10.58	0.858
Target lesion failure rate in 9 months after operation (%)	4.76	4.72	0.953
Incidence of thrombotic events (%)	0.95	0.94	0.945

● Outer diameter lower than the competition



● Pharmacokinetic data shows high Concentration of paclitaxel in tissue and sustained therapeutic effect



Conclusion

There is no statistical difference between Flowty™ and the control group, and it has good safety and effectiveness.